There is a treatment for HIV and cancer, yet it remains unknown to the public. HIV and cancer are the two most deadly diseases, with HIV killing about 3.1 million people and cancers killing 7 million people every year. However, both HIV and cancer can be treated by re-activating macrophages with GcMAF injections. GcMAF is the most potent macrophage activating factor.
To understand what GcMAF is and how it works, the basics of HIV and cancer are necessities. The human immunodeficiency virus's (HIV) origins are unclear, but many speculate that it first came from primates, and then mutated to infect humans. HIV can be transmitted through body fluids and from mother to child. When the virus enters the body, it attacks the body's white blood cells, the cells that fight off diseases. The virus inserts its DNA into the cells to reproduce, and when the new viruses are released, the white blood cell host dies. This leads to a weakened immune system, or AIDS (acquired immune deficiency syndrome), a condition in which diseases can infect the body more easily.
Cancer is a disease that affects cell division, causing cells to multiply out of control, making masses of cancerous cells called tumors. Cancerous cells do not function as they are supposed to; they cease working for the body and only produce more non-functioning cells, causing tissues and organs to shut down because their cells aren't doing any work. Cancer cells continue to spread throughout the body, affecting many organs until it is removed or the person dies.
So how can HIV and cancer both be treated by the same injection? The answer is nagalase, a protein secreted by both HIV-infected cells as well as all cancer tumors. Nagalase is an enzyme that removes a sugar molecule from the protein Gc. The removal of the sugar stops the creation of GcMAF, so macrophages, a type of white blood cell, cannot be activated. To treat the secretion of nagalase in the body, GcMAF is directly injected into the body to activate macrophages. Once the macrophages are activated, they can fight off diseases, targeting the HIV infected cells and cancer tumors.
This treatment has already undergone experimentation and treatment. In 2008, Dr. Nobuto Yamamoto of the Socrates Institute for Therapeutic Immunology published 3 reports on the activation of the immune system, in which he described his experiments GcMAF to balance nagalase levels in HIV and cancer patients during the past decade. In the HIV experiment, 15 HIV infected patients were injected with 100 ng (nanograms are 1 billionth of a gram) of GcMAF weekly, for 18 weeks. By the end of 18 weeks, the nagalase level in their bodies was as low as that of a healthy person, demonstrating the purging of the virus. A similar test with cancer showed equally favorable results. Sixteen prostate cancer patients were given 100 ng of GcMAF weekly. All patients had normal levels of nagalase and were tumor-free after 24 weeks of GcMAF treatment. In both studies, the disease did not return until about 7 years later after the treatment, at which time patients can simply start using GcMAF injections again.
Dr. Yamamoto's studies and clinical trials show that GcMAF can successfully treat cancer and AIDS. Furthermore, there are no apparent negative side effects associated with GcMAF injections, because it is a compound that humans make apparently. Researchers in Japan have also published articles on GcMAF treatment, including Dr. Judah Folkman, a leading researcher in cancer treatment who collaborated with Dr. Yamamoto in his study.
Although this treatment is a potential cure for the leading causes of deaths in the world, it is not yet in major medical publications or the news. Bill Sardi, 2009, writes for the National Health Foundation, "Dr. Yamamoto does not want undue pressure applied to the National Cancer Institute. He says he intends to work with a pharmaceutical company to develop GcMAF. But it has been 6 years since he patented GcMAF... the cancer research industry may be hiding the most promising cure for cancer ever to be documented because it doesn’t know how to profit from it."
But once the GcMAF treatment does come onto public markets, it could impact people globally. Harmful cancer treatments like chemotherapy and radiation may even become obsolete. HIV and AIDS will no longer affect the estimated 42 million people they do now. GcMAF will take cancer and HIV off the top 10 list of deadliest diseases and save millions of people every year.
Bibliography
"Cancer." World Health Organization. Feb. 2009.
"Cancer: Number 1 Killer." BBC News. 9 Nov. 2000.
Sardi, Bill. "GcMAF Cancer Cure Update: A Proven Cure for HIV Infection and Cancer Ignored by Mainstream Medicine and News Media." National Health Federation. 20 May 2009.
"What are the World's Most Deadliest Viruses?." 2009.
Yamamoto, Nobuto. "Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF." Translational Oncology. June 2008.
Yamamoto, Nobuto. "Immunotherapy of HIV-infected patients with Gc protein-derived macrophage activating factor." Journal of Medical Virology. 21 Nov 2008.
